^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Inqovi (decitabine/cedazuridine)

    i
    Other names: ASTX727, ASTX 727, oral C-DEC, DEC-C
    Company:
    Otsuka
    Drug class:
    DNMT inhibitor, Cytidine deaminase inhibitor
    Related drugs:
    8d
    Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PML (Promyelocytic Leukemia)
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
    10d
    Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=93, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    Venclexta (venetoclax) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)
    11d
    ASTX660-03: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Taiho Oncology, Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2026 --> Mar 2026
    Phase classification • Trial completion date
    |
    Inqovi (decitabine/cedazuridine) • tolinapant (ASTX660)
    13d
    DECISIVO: A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy (2025-523238-17-00)
    P1/2, N=50, Not yet recruiting, Fundacion PETHEMA
    New P1/2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    decitabine • Tibsovo (ivosidenib) • Inqovi (decitabine/cedazuridine)
    15d
    Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=27, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Inqovi (decitabine/cedazuridine) • Vonjo (pacritinib)
    16d
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2026 --> Oct 2026
    Trial initiation date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    30d
    A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) (clinicaltrials.gov)
    P2, N=25, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
    |
    EZH2 mutation
    |
    Inqovi (decitabine/cedazuridine)
    1m
    ASTX727-03: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (clinicaltrials.gov)
    P1/2, N=160, Completed, Taiho Oncology, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Inqovi (decitabine/cedazuridine)
    1m
    Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Pamela Munster | Trial completion date: Feb 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    PALB2 mutation • CHEK2 mutation
    |
    Lynparza (olaparib) • Inqovi (decitabine/cedazuridine)
    1m
    PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Otsuka Beijing Research Institute | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Inqovi (decitabine/cedazuridine)
    1m
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027 | Initiation date: Oct 2025 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    2ms
    Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    decitabine • Inqovi (decitabine/cedazuridine)